PreciseMent
AI-driven Molecular Testing to Personalize Mental Health Treatment
Company Overview
Snapshot
Founded in January 2021 by Rubek Aknin and Sonia Berreh-Aknin, PreciseMent operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technology.
Business overview
PreciseMent is a Health Tech & Life Sciences company focused on personalizing mental health treatment through AI-driven molecular testing. The company's core technology utilizes a unique methodology that combines biology, multiomics technology, and artificial intelligence to identify individual patient differences at the genetic and molecular level, creating biosignatures. PreciseMent aims to streamline the process of matching individuals with psychiatric and mood disorders to the most appropriate treatments, serving patients, physicians, and clinical research organizations within the digital medical diagnostics sector.
Log in to access full profile ›Company Intelligence Q&A
- What is PreciseMent's primary focus?
- PreciseMent focuses on personalizing mental health treatment by using AI-driven molecular testing to match individuals with psychiatric and mood disorders to the most appropriate therapies.
- When was PreciseMent founded?
- PreciseMent was founded in January 2021.
- Who are the co-founders of PreciseMent?
- PreciseMent was co-founded by Rubek Aknin and Sonia Berreh-Aknin.
- What technology does PreciseMent utilize?
- PreciseMent utilizes a unique methodology that integrates biology, multiomics technology, and artificial intelligence to capture individual patient differences at the genetic and molecular level, forming biosignatures.
- Which markets does PreciseMent target?
- PreciseMent targets patients, physicians, and clinical research organizations within the digital medical diagnostics sector, aiming to alleviate the burden associated with finding effective treatments for psychiatric and mood disorders.